drugset
drugset / Trial / NCT05448781

Recombinant Human Angioendostatin /PD-1 Mab Combined With First-line Chemotherapy in the Treatment of Driver Gene Negative Advanced NSCLC

NCT05448781 ↗

Phase 2 Unknown 38 enrolled Affiliated Cancer Hospital & Institute of Guangzhou Medical University
NaSingle-groupOpen-labelTreatment

Summary

To evaluate the efficacy and safety of recombinant human endostatin /PD-1 mab combined with first-line chemotherapy in the treatment of driver gene negative advanced non-small cell lung cancer.

Timeline

Start
2022-07-20
Primary completion
2023-07-20
Completion
2023-12-20

Drugs

EvaluationDrugModalityDoseRoute
Subject Endostar Protein / enzyme biologic 210 mg Intravenous
Background Carboplatin Small molecule 5 unknown Intravenous
Background Paclitaxel Small molecule 175 mg/m2 Intravenous
Background Paclitaxel Small molecule 260 mg/m2 Intravenous
Background Pemetrexed Small molecule 500 mg/m2 Intravenous
Background Tirelizumab Monoclonal antibody 200 mg —

Indications

non-small cell lung carcinoma